This lipid is one of the important adjuvants in lipid nanoparticles (LNPs) used in COVID-19 vaccines. Rapid advances in research create
including vaccines against infectious diseases and cancer immunotherapy.
The supply is increasing PhytoChol® supporting the growth trajectory of Evonik’s Healthcare business, which is part of the life sciences division, Nutrition & Care. By expanding PhytoChol® manufacturing capabilities, Nutrition & Care strengthens its portfolio of system solutions for advanced drug delivery.
Parts aim increase the rate of system solutions from 20 percent today, to more than 50% by 2030.
“As one of the few suppliers of high-quality, non-animal cholesterol to the pharmaceutical industry, we are proud to offer innovators a key excipient for a wide range of methods. improved nucleic acid treatment,” Dr. Thomas Riermeier, head of Evonik’s Healthcare business said. “Increasing our supply of PhytoChol® is a timely step to further advance the development of mRNA and gene therapies as well as biopharmaceutical cell culture applications.”
PhytoChol® is not of animal origin and, therefore, reduces the risks associated with cholesterol from animal origin, such as undesirable immune responses and inconsistent quality. It is a necessary adjuvant for the delivery of large molecules such as lipid-based mRNAs. PhytoChol® is available in two grades to suit the specific needs of injectables and biopharmaceutical cell culture applications.
As an integrated contract development and manufacturing organization (CDMO), Evonik Health Care has been a leader in innovative drug delivery for decades, supporting pharmaceutical companies worldwide with end-to-end CDMO service for the development and manufacture of complex injectable drug products.